FEATURE ARTICLES

Balancing Biopharma’s Bright Future Against Its Tarnished Image —  Insights From 6 Retired CEOs
Balancing Biopharma’s Bright Future Against Its Tarnished Image — Insights From 6 Retired CEOs

Find out what life is like after retiring from a pharma CEO role. These 6 leaders  speak — unrestrained by corporate lawyers and PR teams — about the current state of the industry.

More featured articles

ALSO IN THIS MONTH'S ISSUE

More from Life Science Leader

SPECIAL EDITION: 2017 CRO LEADERSHIP AWARDS

 

Read all the exclusive content — including who our CRO award winners are this year — in the 2017 CRO Leadership Awards Special Edition.

 

 

WEB-EXCLUSIVE EDITORIAL

  • 5 Tips For Orphan Drug Development In A Price-Sensitive Payer Environment
    5 Tips For Orphan Drug Development In A Price-Sensitive Payer Environment

    The first installment in this two-part series examined rising costs associated with orphan drugs and two related case studies. This second part provides actionable suggestions for developers.

  • How To Create A Spirit Of Independence Among Your Team
    How To Create A Spirit Of Independence Among Your Team

    Welcome to the premier edition of Dr. Liz on Leadership! In my new, monthly Life Science Leader column, I will bring you practical tools and advice to help you, your team, and your organization thrive in today’s rapidly changing healthcare environment.

  • Using Social Media To Build Patient Trust
    Using Social Media To Build Patient Trust

    Understanding the proper role of social media is an important challenge for pharmaceutical companies when it comes to “connecting” with potential patients and building their levels of trust. In 2017, strategies that involve traditional mass media — such as TV and print ads — are far from dead; however, social media offers clear advantages to building recognition for a drug — and awareness of its efficacy — in ways that can be targeted to very specific audiences.

  • Responding To Regulatory Inspection Observations: Do’s and Don’ts
    Responding To Regulatory Inspection Observations: Do’s and Don’ts

    It’s Friday, it’s late, and you are just leaving for the weekend. The inspection you hosted two weeks ago remains a painful memory. The exit meeting didn’t go well — five major observations, all relating to your quality system. When your boss enters your office, you know it’s not to wish you a good weekend. 

  • Pharma's Vital Interest In Tracking State Biosimilar Substitution Laws
    Pharma's Vital Interest In Tracking State Biosimilar Substitution Laws

    State lawmakers continue to spearhead legislative boundaries to automatic biosimilar substitution at a rapid clip across the nation, with 33 states and Puerto Rico having taken action and with bills pending in eight more states.

More web-exclusive editorial

BEYOND THE PRINTED PAGE

  • Successful Transformations Require A Post-Period Of Reflection

    While it is a little early in the Merck Manufacturing Division (MMD) transformation to determine what, if anything, he would have done differently, it is likely Sanat Chattopadhyay will explore this exercise in the near future. “Every time I complete an assignment, whether a transformation or consolidation, I reflect on what was done and realize that there are always some missteps,” shares Chattopadhyay, the president of MMD. “For example, when I was in India, I did the transformation from internal to external manufacturing too fast. Sometime I could benefit from right-sizing my own ambition,” he says with a smile.

  • What Would 6 Industry Icons Do Differently If Given The Chance To Be CEO Again?

    In the July 2017, Life Science Leader magazine we will be publishing the article — Balancing Biopharma’s Bright Future Against Its Tarnished Image — 6 Retired CEOs Share Insights For Today’s Industry Leaders. The story features six former CEOs: Mike Bonney (Cubist); Hank McKinnell, Ph.D., (Pfizer); Francois Nader, M.D., (NPS Pharmaceuticals); David Pyott (Allergan); Stephen Sherwin, M.D., (Cell Genesys); and Henri Termeer (Genzyme). As each of these executive was gracious enough to give us an hour of their time, we encountered a slight problem — too many great insights to be included within all the pages of a print publication.

  • Why Would Human Health Companies Want To Partner With Zoetis?

    When Zoetis, the former animal health business unit of Pfizer, was spun off as an independent company via an IPO in February 2013 (see Life Science Leader’s June 2017 cover feature), overnight it became the world’s largest publically traded animal health company. And while no longer part of one of the largest human health companies in the world, this doesn’t mean that a company focused on developing products just for animals isn’t interested in collaborating with biopharmas dedicated to creating therapeutics for people. Scott Brown, D.V.M., Ph.D., is the executive responsible for brokering such collaborations. The VP of external innovation elaborates on some of the challenges faced by Zoetis post IPO in creating research collaborations, as well as why human-health oriented companies might want to consider collaborating with an animal–health-focused company like Zoetis.

More Beyond The Printed Page Articles

LIFE SCIENCE TRAINING INSTITUTE COURSES

Effective Batch Record Review - Getting It Right The First Time August 14, 2017
1pm-2:30pm EDT, Online Training
CAPA and Root Cause Analysis Essentials Post ICH GCP E6 (R2) Addendum August 21, 2017
11:00am- 12:00pm EDT, Online Training
How To Establish The Number of Runs Required For Process Validation August 23, 2017
1:00 - 2:00 PM EDT, Online Training
Monitoring Plan Development: Post ICH GCP E6 (R2) Addendum August 25, 2017
11:00am- 12:00pm EDT, Online Training
More training courses

JULY 2017 DIGITAL EDITION

2017 CRO AWARDS SPECIAL EDITION

2017 CMO AWARDS SPECIAL EDITION

BLOGS

More blogs

@LIFESCILEADER1

 UPCOMING EVENTS

Clinical Study Requirements – Understanding Differences Between the US and EU July 25, 2017
1pm-2:30pm EST, Online Training
Price:  $299 - Includes Bonus Handouts!
NGS and Clinical Applications Congress: USA July 25 - 26, 2017
Philadelphia, PA
Medical Affairs Leaders Forum USA July 25 - 27, 2017
Princeton, NJ
Simplifying Your Quality System While Implementing ISO 13485:2016 Requirements – Strategies for Success July 27, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
More events